| Literature DB >> 27164979 |
Yong Su1,2, Chuan-Wei Mo3, Wan-Qin Cheng1,2, Lei Wang1,2, Qian Xu3, Zu-Chun Wu4, Zhe-Li Wu4, Li-Zhi Liu1, Xin-Lin Chen5.
Abstract
BACKGROUND: The aim was to develop and validate the quality of life scale for nasopharyngeal carcinoma (NPC) patients, the QOL-NPC (version 2), a specific instrument to measure quality of life for NPC patients.Entities:
Keywords: Health-related quality of life; QOL-NPC; Reliability; Responsiveness; Validity
Mesh:
Year: 2016 PMID: 27164979 PMCID: PMC4862168 DOI: 10.1186/s12955-016-0480-0
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Fig. 1Steps towards development and validation procedure
Characteristics of the patients
| Number (%, | Number (%, | Number (%, | |
|---|---|---|---|
| Gender | |||
| Male | 341 (70.0) | 58 (72.5) | 43 (71.7) |
| Female | 146 (30.0) | 22 (27.5) | 17 (28.3) |
| Educational degree | |||
| ≤9 years | 272 (55.9) | 60 (75.0) | 45 (75.0) |
| ~12 years | 180 (37.0) | 14 (17.5) | 12 (20.0) |
| >12 years | 35 (7.2) | 6 (7.5) | 3 (5.0) |
| Marriage stage | |||
| Unmarried | 34 (7.0) | 12 (15.0) | 9 (15.0) |
| Married | 453 (93.0) | 68 (85.0) | 51 (85.0) |
| Dialect | |||
| Cantonese | 335 (68.8) | 53 (66.3) | 38 (63.3) |
| Hakka | 87 (17.9) | 14 (17.5) | 12 (20.0) |
| Chaoshanese | 48 (9.9) | 5 (6.3) | 5 (8.3) |
| Others | 17 (3.5) | 8 (10.0) | 5 (8.3) |
| Source of the patients | |||
| In-patients | 80 (16.4) | 80 (100.0) | 60 (100.0) |
| Out-patients | 407 (83.6) | 0 (0.0) | 0 (0.0) |
| Pathological type | |||
| Squamous cell | 22 (4.5) | 6 (7.5) | 5 (8.3) |
| Differentiation type | 32 (6.6) | 9 (11.3) | 5 (8.3) |
| Undifferentiated type | 433 (88.9) | 65 (81.3) | 50 (83.3) |
| UICC stage | |||
| I stage | 22 (4.5) | 0 (0.0) | 0 (0.0) |
| II stage | 78 (16.0) | 12 (15.0) | 4 (6.7) |
| III stage | 227 (46.6) | 36 (45.0) | 28 (46.7) |
| IV stage | 160 (32.9) | 32 (40.0) | 28 (46.7) |
| Radiotherapy | |||
| IMRT | 294 (60.4) | 72 (90.0) | 60 (100.0) |
| Three-dimensional RT | 47 (9.7) | 2 (2.5) | 0 (0.0) |
| Conventional RT | 86 (17.7) | 4 (5.0) | 0 (0.0) |
| No | 60 (12.3) | 2 (2.5) | 0 (0.0) |
| Other disease | |||
| Yes | 98 (20.1) | 60 (75.0) | 47 (78.3) |
| No | 389 (79.9) | 20 (25.0) | 13 (21.7) |
aThe patients were used for the retest test
bThe patients were used for the responsiveness test
Missing data, mean and SD for each item (n = 487)
| Score 1 | Score 2 | Score 3 | Score 4 | Score 5 | Missing (%) | Mean | SD | |
|---|---|---|---|---|---|---|---|---|
| PH1 | 13 | 92 | 195 | 170 | 13 | 4(0.8) | 3.16 | 0.86 |
| PH2 | 24 | 105 | 170 | 161 | 20 | 7(1.4) | 3.10 | 0.96 |
| PH3 | 28 | 184 | 191 | 60 | 10 | 14(2.9) | 2.66 | 0.85 |
| PH4 | 14 | 63 | 155 | 166 | 82 | 7(1.4) | 3.50 | 1.02 |
| PH5 | 13 | 40 | 96 | 209 | 125 | 4(0.8) | 3.81 | 1.00 |
| PH6 | 20 | 60 | 101 | 171 | 129 | 6(1.2) | 3.68 | 1.12 |
| PH7 | 14 | 56 | 83 | 213 | 117 | 4(0.8) | 3.75 | 1.04 |
| PH8 | 16 | 70 | 129 | 183 | 86 | 3(0.6) | 3.52 | 1.05 |
| PS1 | 5 | 30 | 146 | 236 | 63 | 7(1.4) | 3.67 | 0.82 |
| PS2 | 33 | 281 | 101 | 59 | 12 | 1(0.2) | 2.46 | 0.88 |
| PS3 | 48 | 235 | 64 | 113 | 23 | 4(0.8) | 2.64 | 1.09 |
| PS4 | 35 | 207 | 168 | 59 | 16 | 2(0.4) | 2.62 | 0.91 |
| PS5 | 10 | 26 | 116 | 293 | 39 | 3(0.6) | 3.67 | 0.78 |
| SO1 | 8 | 17 | 122 | 281 | 55 | 4(0.8) | 3.74 | 0.77 |
| SO2 | 5 | 40 | 86 | 261 | 92 | 3(0.6) | 3.82 | 0.87 |
| SO3 | 38 | 158 | 63 | 160 | 67 | 1(0.2) | 3.12 | 1.23 |
| SO4 | 34 | 217 | 95 | 107 | 31 | 3(0.6) | 2.76 | 1.07 |
| SO5 | 5 | 46 | 184 | 220 | 28 | 4(0.8) | 3.46 | 0.79 |
| SE1 | 32 | 117 | 182 | 136 | 17 | 3(0.6) | 2.98 | 0.96 |
| SE2 | 31 | 76 | 141 | 147 | 87 | 5(1.0) | 3.38 | 1.14 |
| SE3 | 11 | 41 | 122 | 205 | 98 | 10(2.1) | 3.71 | 0.96 |
| SE4 | 7 | 38 | 111 | 184 | 138 | 9(1.8) | 3.85 | 0.98 |
| SE5 | 11 | 62 | 105 | 192 | 105 | 12(2.5) | 3.67 | 1.03 |
| SE6 | 14 | 62 | 126 | 181 | 93 | 11(2.3) | 3.58 | 1.04 |
| SE7 | 9 | 55 | 138 | 168 | 102 | 15(3.1) | 3.63 | 1.01 |
| SE8 | 6 | 34 | 96 | 197 | 136 | 18(3.7) | 3.90 | 0.94 |
PHx the xth item of the PH domain, score 1 lowest QOL, score 5 highest QOL, SD standard deviation
Descriptive statistics and reliability of the QOL-NPC (n = 487)
| Domain | No. of items | Mean ± SD | Range of score | Cronbach’s alpha | Split-half coefficient | ICC (95 % CI) |
|---|---|---|---|---|---|---|
| PH | 8 | 60.0 ± 16.9 | (6.3, 100.0) | 0.80 | 0.83 | 0.87 (0.85, 0.89) |
| PS | 5 | 50.3 ± 15.5 | (0.0, 100.0) | 0.72 | 0.77 | 0.88 (0.86, 0.90) |
| SO | 5 | 59.4 ± 17.2 | (0.0, 100.0) | 0.76 | 0.81 | 0.82 (0.78, 0.86) |
| SE | 8 | 64.5 ± 17.6 | (3.1, 100.0) | 0.84 | 0.84 | 0.88 (0.84, 0.92) |
Items-domains correlation analysis of QOL-NPC (n = 487)
| Correlation with item | Factor loading of CFA | ||||
|---|---|---|---|---|---|
| PH | PS | SO | SE | ||
| PH1 | 0.54 | 0.31 | 0.27 | 0.29 | 0.67 |
| PH2 | 0.72 | 0.33 | 0.34 | 0.39 | 0.72 |
| PH3 | 0.64 | 0.30 | 0.34 | 0.39 | 0.66 |
| PH4 | 0.63 | 0.15 | 0.29 | 0.45 | 0.59 |
| PH5 | 0.48 | 0.09 | 0.23 | 0.29 | 0.51 |
| PH6 | 0.77 | 0.29 | 0.22 | 0.55 | 0.65 |
| PH7 | 0.47 | 0.22 | 0.19 | 0.32 | 0.51 |
| PH8 | 0.64 | 0.20 | 0.21 | 0.44 | 0.55 |
| PS1 | 0.36 | 0.61 | 0.42 | 0.35 | 0.53 |
| PS2 | 0.22 | 0.79 | 0.35 | 0.26 | 0.72 |
| PS3 | 0.17 | 0.74 | 0.25 | 0.20 | 0.57 |
| PS4 | 0.37 | 0.80 | 0.40 | 0.37 | 0.81 |
| PS5 | 0.22 | 0.53 | 0.27 | 0.16 | 0.54 |
| SO1 | 0.21 | 0.26 | 0.58 | 0.17 | 0.47 |
| SO2 | 0.26 | 0.24 | 0.61 | 0.31 | 0.47 |
| SO3 | 0.19 | 0.31 | 0.80 | 0.21 | 0.63 |
| SO4 | 0.38 | 0.45 | 0.78 | 0.28 | 0.74 |
| SO5 | 0.41 | 0.43 | 0.71 | 0.33 | 0.70 |
| SE1 | 0.52 | 0.32 | 0.22 | 0.65 | 0.63 |
| SE2 | 0.71 | 0.33 | 0.24 | 0.74 | 0.76 |
| SE3 | 0.46 | 0.26 | 0.24 | 0.71 | 0.66 |
| SE4 | 0.45 | 0.25 | 0.28 | 0.70 | 0.65 |
| SE5 | 0.31 | 0.16 | 0.21 | 0.69 | 0.56 |
| SE6 | 0.25 | 0.20 | 0.26 | 0.63 | 0.50 |
| SE7 | 0.47 | 0.35 | 0.34 | 0.73 | 0.66 |
| SE8 | 0.41 | 0.29 | 0.27 | 0.68 | 0.59 |
Fig. 2Results of CFA
The domain scores (mean ± SD) of patients among different RT stages and RT method
| n | PH | PS | SO | SE | |
|---|---|---|---|---|---|
| RT stages | |||||
| Before RT | 60 | 65.9 ± 15.5 | 54.5 ± 15.8 | 60.8 ± 17.6 | 71.6 ± 17.0 |
| During RT | 171 | 54.0 ± 14.9 | 47.4 ± 13.6 | 58.3 ± 15.7 | 59.2 ± 17.9 |
| ≤1 year after RT | 145 | 59.3 ± 14.2 | 48.5 ± 16.5 | 57.5 ± 15.6 | 62.6 ± 16.3 |
| ~5 years after RT | 65 | 63.5 ± 14.1 | 55.1 ± 16.3 | 63.8 ± 17.6 | 70.5 ± 15.9 |
| >5 years after RT | 46 | 72.3 ± 17.4 | 54.3 ± 14.7 | 61.3 ± 24.2 | 73.0 ± 15.4 |
|
| <0.001 | <0.001 | 0.100 | <0.001 | |
| RT method | |||||
| IMRT | 294 | 61.3 ± 15.7 | 51.5 ± 15.2 | 61.8 ± 16.4 | 66.8 ± 16.7 |
| Three-dimensional RT | 46 | 56.8 ± 13.2 | 44.5 ± 14.1 | 56.7 ± 17.1 | 60.6 ± 17.5 |
| Conventional RT | 86 | 53.4 ± 16.1 | 46.3 ± 15.6 | 51.8 ± 17.7 | 53.9 ± 16.6 |
| No RT | 60 | 65.9 ± 15.5 | 54.5 ± 15.8 | 60.8 ± 17.6 | 71.6 ± 17.0 |
|
| <0.001 | <0.001 | <0.001 | <0.001 |
RT radiotherapy, IMRT intensity-modulated radiotherapy
Change in scores and effect size from baseline to the end of radiotherapy (n = 60)
| Baseline score | Change scoresa | 95 % CI of change scores | Effect sizeb | |
|---|---|---|---|---|
| PH | 65.9 ± 15.5 | −4.9 ± 6.4 | (3.2, 6.5) | −0.31 |
| PS | 54.5 ± 15.8 | −3.8 ± 5.3 | (2.4, 5.2) | −0.24 |
| SO | 60.8 ± 17.6 | −3.9 ± 6.0 | (2.4, 5.5) | −0.22 |
| SE | 71.6 ± 17.0 | −5.9 ± 5.4 | (4.5, 7.3) | −0.82 |
Change scoresa, the score at the end of radiotherapy minus the baseline, −100 (maximum worsening) to +100 (maximum improvement)
Effect sizeb, calculated as the change in scores divided by the SD of the baseline score
| PH1. Sleep | poor | fair | good | very good | excellent |
| PH2. Appetite | poor | fair | good | very good | excellent |
| PH3. Satisfaction with appearance | not at all | a little bit | moderate | quite a bit | extreme |
| PH4. Weight loss | extreme | quite a bit | moderate | a little bit | not at all |
| PH5. Tiredness | extreme | quite a bit | moderate | a little bit | not at all |
| PH6. Headache | extreme | quite a bit | moderate | a little bit | not at all |
| PH7. Nasal tampon or nasal bleeding | extreme | quite a bit | moderate | a little bit | not at all |
| PH8. Coughing while swallowing | extreme | quite a bit | moderate | a little bit | not at all |
| PS1. Feeling lives to be meaningful | not at all | a little bit | moderate | quite a bit | extreme |
| PS2. Satisfaction with treatment effect | not at all | a little bit | moderate | quite a bit | extreme |
| PS3. Worries about impact of disease | extreme | quite a bit | moderate | a little bit | not at all |
| PS4. Worries about inheritance of disease | extreme | quite a bit | moderate | a little bit | not at all |
| PS5. Mental stress | extreme | quite a bit | moderate | a little bit | not at all |
| SO1. Satisfaction with interpersonal relations | not at all | a little bit | moderate | quite a bit | extreme |
| SO2. Satisfaction with ability of work and daily life | not at all | a little bit | moderate | quite a bit | extreme |
| SO3. Difficulty in communication | extreme | quite a bit | moderate | a little bit | not at all |
| SO4. Influence of role in family and work | extreme | quite a bit | moderate | a little bit | not at all |
| SO5. Influence of social activities | extreme | quite a bit | moderate | a little bit | not at all |
| SE1. Dry mouth | extreme | quite a bit | moderate | a little bit | not at all |
| SE2. Throat pain | extreme | quite a bit | moderate | a little bit | not at all |
| SE3. Harmfulness in head-neck skin | extreme | quite a bit | moderate | a little bit | not at all |
| SE4. Difficulty in opening mouth | extreme | quite a bit | moderate | a little bit | not at all |
| SE5. Loosed and damaged teeth | extreme | quite a bit | moderate | a little bit | not at all |
| SE6. Hearing loss | extreme | quite a bit | moderate | a little bit | not at all |
| SE7. Radioactive rhinitis | extreme | quite a bit | moderate | a little bit | not at all |
| SE8. Memory loss | extreme | quite a bit | moderate | a little bit | not at all |